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Background: Hypertrophic scarring is a highly prevalent condition clinically and results from a decreased number
of apoptotic fibroblasts and over-abundant production of collagen during scar formation following wound healing.
Our previous studies indicated that Shikonin, an active component extracted from Radix Arnebiae, induces apoptosis
and reduces collagen production in hypertrophic scar-derived fibroblasts. In the study reported here, we further
evaluate the potential use of Shikonin as a novel scar remediation therapy by examining the effects of Shikonin on
both keratinocytes and fibroblasts using Transwell® co-culture techniques. The underlying mechanisms were also
revealed. In addition, effects of Shikonin on the expression of cytokines in Transwell co-culture “conditioned”
medium were investigated.
Results: Our results indicate that Shikonin preferentially inhibits cell proliferation and induces apoptosis in
fibroblasts without affecting keratinocyte function. In addition, we found that the proliferation-inhibiting and
apoptosis-inducing abilities of SHI might be triggered via MAPK and Bcl-2/Caspase 3 signalling pathways.
Furthermore, SHI has been found to attenuate the expression of TGF-β1 in Transwell co-cultured “conditioned”
medium.
Conclusions: The data generated from this study provides further evidence that supports the potential use of
Shikonin as a novel scar remediation therapy.Background
Hypertrophic scarring (HS) is a highly prevalent condition
that occurs after burns and surgical incision [1]. Pain, itch-
ing, stiffness, loss of sensation and loss of joint mobility
have been reported by patients with HS [2]. Although the
exact mechanisms underpinning HS formation are still
elusive, the formation of HS results from the dysregulation
of the wound healing process [3]. When sufficient collagen
is formed at the end of wound healing, the number of
apoptotic fibroblasts sharply increases. In HS, however,
large amounts of fibroblasts persist, producing an over-
abundance of collagen [4, 5]. In addition, delayed kera-
tinocyte (Kc) function in terms of re-epithelialization also
leads to HS formation [6]. Furthermore, exaggerated in-
flammation may lead to HS formation by prolonging the
wound healing process [7].* Correspondence: c3.fan@connect.qut.edu.au
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article, unless otherwise stated.Current scar-remediation therapies are less than satisfac-
tory for a number of reasons [8], hence attention has been
given to the potential benefits of natural products as an
alternative strategy to remediate scars [9]. Shikonin (SHI),
an active component extracted from the Chinese herb
Radix Arnebiae, has been widely demonstrated to possess
various biological activities, such as anti-inflammatory,
anti-bacterial, anti-angiogenic and anti-tumorigenic proper-
ties [10]. Most importantly, SHI has been extensively
reported to induce apoptosis in many different cancer cell
lines [11, 12]. Based on the importance of apoptosis in HS
formation and the apoptosis-inducing ability of SHI, we
therefore investigated the effects of SHI on hypertrophic
scar-derived human skin fibroblasts (HSF). Our preliminary
studies indicated that SHI reduces HSF proliferation
and collagen production in a dose-dependent manner
and the underlying mechanisms have also been partly
revealed (Article in press).
Given that wound healing is a complex process that re-
quires the participation of different types of cells, such as
Kc and fibroblasts, we have now progressed to evaluatings distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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well® co-culture technique and investigated the underlying
molecular mechanisms. In addition, considerable evidence
indicates that crosstalk between Kc and fibroblasts plays
an essential role in both wound healing and HS formation.
This crosstalk is mediated by soluble cytokines and
growth factors, rather than by direct interaction [13].
Thus, the paracrine effects of SHI on cytokines in Kc and
fibroblast were also investigated.Methods
Preparation of reagents
SHI powder was produced by the National Institute for
the Control of Pharmaceutical and Biological Products,
China. SHI was dissolved in Dimethyl sulfoxide (DMSO;
Sigma-Aldrich, Australia) as a stock solution and stored
at −20 °C before use. Phospho-ERK inhibitor U0126
(#9903) and Phospho-JNK inhibitor SP600125 (#8177)
were purchased from Cell Signalling, Australia. U0126
and SP600125 were diluted into DMSO at 10 μM and
50 μM before use.Cell culture
Primary human Kc were isolated from native human
skin obtained from consenting donors at St Andrew’s
Hospital (Brisbane, Australia) with human ethics ap-
proval from both the hospital (2003/46) and the Queens-
land University of Technology (1300000063). Kc were
cultured in “Green’s” medium containing 10 % fetal calf
serum (FCS; Hyclone, Australia) following methods pre-
viously described by Rheinwald and Green (1975) and
others [14, 15]. HSF were purchased from Cell Research
Corporation (Singapore). These cells were routinely cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM;
Invitrogen, Australia) containing 10 % FCS at 37 °C in
an incubator with 5 % CO2.Cell proliferation assay
The effects of SHI on cell proliferation were investigated
using the CyQUANT assay (Invitrogen). Kc (4 × 104
cells/well) and HSF (6 × 104 cells/well) were seeded into
the 12-well Transwell® (Kc in the insert and HSF in the
lower chamber, Corning, USA) for 48 h based on previ-
ously optimized cell density studies. Serial dilutions of
SHI were then applied to the Transwell® resulting in final
concentrations of 0.5, 1 and 3 μg/mL. A group without
SHI treatment was also included as a control. After 72 h
incubation, the CyQUANT reagents were applied as per
the manufacturer’s instructions and cell proliferation
was measured at λex 485P, λem 520P using a Polar Star
Optima Microplate Reader (Optima, Germany).Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay
Apoptosis was detected using the TUNEL assay (Roche
Applied Science, Australia) [16]. Kc and HSF were
seeded and treated with SHI as described above. Follow-
ing 48 h of incubation at 37 °C, the cells were first fixed
in 3.7 % para-formaldehyde and then permeabilised in
0.2 % Triton X-100/PBS (Sigma-Aldrich). After incuba-
tion with the TUNEL reaction mixture for 1 h at 37 °C,
a nuclear stain (4′, 6-diamidino-2-phenylindole (DAPI))
was added. Fluorescence images were then captured
using a Nikon Eclipse TE2000-U microscope (Nikon,
Australia).
Flow cytometry
Flow cytometry was also used to indentify SHI-induced
apoptosis in Kc and HSF using the Dead Cell Apoptosis
Kit with Alexa® Fluor 488 annexin V and PI assay kit
(V13241, Life Technologies). Phosphatidyl serine (PS) is
normally located on the cytoplasmic surface of the cell
membrane, whereas it translocates from the inner to the
outer leaflet of the membrane when apoptosis occurs
[17]. Annexin V is the protein that binds with PS, there-
fore apoptosis can be identified using fluorophore-
labeled Annexin V. Briefly, Kc and HSF were treated as
described above. The cells were harvested after 12 h of
treatment, followed by washing with cold PBS twice.
The cells were then resuspended in annexin-binding
buffer at 2 × 105 cells/mL and stained with Alexa® Fluor
488 annexin V and propidium iodide (PI) for 15 min at
room temperature. The florescence was then measured
at 530–575 nm emission and 488 nm excitation using
FACSAria™ III Cell Sorter (Becton Dickinson, USA).
Western blot
SHI-induced changes in protein expression were deter-
mined by Western Blot. Kc and HSF were first seeded
and treated with SHI. Whole lysates from cells, exclud-
ing medium, were collected in a lysis buffer containing
150 mM NaCl, 50 mM Tris, 1 % sodium dodecyl
sulphate, 1 % Triton, protease inhibitor cocktail (Roche
Applied Science), 2 mM sodium vanadate and 10 mM
sodium fluoride after 24 and 48 h of exposure to SHI.
The protein concentrations were measured using the
Bicinchoninic Acid (BCA; Pierce, USA) assay. Equal
amounts of protein in each group were prepared and
separated using 12 % sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE) and were then
transferred onto nitrocellulose membranes (Bio Rad,
USA). The membranes were incubated with primary
antibodies overnight at 4 °C in Odyssey blocking buffer
(LI-COR® Biosciences, USA). Primary antibodies in-
cluded: ERK1/2, p-ERK1/2, JNK1/2, p-JNK1/2, Caspase
3, Bcl-2, NF-κB, p-NF-κB, I-κB, p-I-κB, IKK-α/β and
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p-p38α/β from Santa Cruz Biotechnology, USA; and
GAPDH from Sigma-Aldrich. Secondary antibodies
conjugated with AlexaFluor 680 or 800 (Invitrogen) were
then applied as species appropriate. Images were cap-
tured and analysed using the Odyssey Infrared Imaging
system and software (LI-COR® Biosciences).Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
qRT-PCR was used to evaluate the expression of genes
in cells treated with SHI. Genes of interest and their
respective primers are listed in Table 1. The cells were
seeded into Transwells and treated with SHI for 24 h.
Total RNA was then extracted from the cells using the
Qiagen RNeasy Mini kit (Qiagen, Australia), as per the
manufacturer’s protocol. First strand cDNA synthesis
was performed using SuperscriptTM III Reverse Tran-
scriptase (Invitrogen). qRT-PCR was then performed
using the SYBR Green method in an ABI 7500 Thermal
Cycler (Applied Biosystems, Australia).Enzyme-linked immunosorbent assay (ELISA)
Expression of transforming growth factor beta one
(TGF-β1) in Transwell “conditioned” media was deter-
mined using ELISA assay kits (Invitrogen). Briefly, media
in the Transwell® were collected at 24 and 48 h following
SHI treatment. The ELISA assay was then performed as
per the manufacturer’s instructions. Expression of TGF-Table 1 Primers used in qRT-PCR
Protein name Corresponding
gene name
Primers: Forward (F) & Reverse (R)
Caspase 3 CASP3 F: 5’-CGGAAGCAGTGCAGACGCGG-3’
R: 5’-GCTGCGAGCACTCACGAAACTCTTC-3’
Bcl-2 BCL2 F: 5’-TCAACCGGGAGATGTCGCCCC-3’
R: 5’-ACAAAGGCATCCCAGCCTCCGTT-3’






Collagen I COL1A1 F: 5’-ACGAAGACATCCCACCAATC-3’
R: 5’-AGATCACGTCATCGCACAAC-3’
Collagen III COL3A1 F: 5’-GCCTCCCGGAAGTCAAGGAGAAAG-
3’
R: 5’-CTTTAGGACCGGGGAAGCCCATG-3’
αSMA αSMA F: 5’-CTGCTGAGCGTGAGATTGTC-3’
R: 5’-CTCAAGGGAGGATGAGGATG-3’
GAPDH GAPDH F:5’-TCTTTTGCGTCGCCAGCCGAG-3’
R:5’-TGACCAGGCGCCCAATACGAC-3’β1 was measured at 450 nm using a Microplate Reader
(Optima).
Statistical analysis
Triplicate samples were assayed in each experiment and
each experiment was replicated three times, each time
using cells obtained from three different patients. The
data obtained in each experiment were first converted to
the percentage of the untreated control, and then the
converted data from 3 different patients were pooled
together as the final average data. One-way ANOVA and
Tukey’s post-hoc test were applied and p < 0.05 was con-
sidered to be statistically significant.
Results
SHI inhibits cell proliferation and induces apoptosis in Kc
and HSF
To identify the effects of SHI on cell proliferation, Kc
and HSF were treated with different concentrations of
SHI (0.5, 1 and 3 μg/mL) (Fig. 1a). SHI at 0.5 μg/mL
showed no significant effects on both Kc and HSF prolif-
eration compared to the untreated control (p < 0.05).
SHI at 1 μg/mL decreased HSF proliferation by 21.5 % ±
3.7 % compared to the untreated control (p < 0.05), how-
ever, no inhibitory effect on Kc proliferation was detected
at this concentration of SHI. Kc and HSF proliferation
were 40.5 % ± 5.2 % and 50.7 % ± 7.6 % below the un-
treated control (p < 0.05) when exposed at SHI 3 μg/mL,
respectively. Taken together, these data indicate SHI re-
duces both Kc and HSF proliferation in a dose-dependent
manner with higher concentrations required, however, to
elicit effects on Kc compared to HSF. Specially, 1 μg/mL
SHI inhibits HSF but not Kc proliferation.
DNA fragmentation is an important hallmark indicating
apoptosis and can be detected through the addition of
TUNEL reagent, resulting in green emissions [16]. Obser-
vation of images captured of the cells when viewed with
fluorescence microscopy (Fig. 1b) reveals that no apop-
totic cells (green emissions) were detected in either Kc or
HSF when treated with SHI 0.5 μg/mL. Apoptotic cells
were observed in HSF but not in Kc when exposed to SHI
at 1 μg/mL. SHI at 3 μg/mL, however, induced apoptosis
in both Kc and HSF. Quantitative analysis of the
TUNEL assay images revealed that SHI at 3 μg/mL
induces 81.0 % ± 8.1 % and 92.5 % ± 3.7 % of the cells
present to undergo apoptosis in Kc and HSF, respectively
(Fig. 1c). Further, SHI at 1 μg/mL triggers 33.7 % ± 15.2 %
of the HSF to undergo apoptosis. These results demon-
strate that SHI induces apoptosis in both Kc and HSF in a
dose-dependent manner and that Kc are more resistant to
SHI-induced apoptosis than HSF.
Data from flow cytometry (Fig. 2a & b) indicated that
SHI at either 1 or 3 μg/mL showed no effect on Kc apop-
tosis compared to the untreated group. However, SHI at
Fig. 1 Effects of SHI on cell proliferation and apoptosis. a Cell proliferation. Kc and HSF were co-cultured and treated with SHI (0.5, 1 and 3 μg/mL) for
72 h. Cell proliferation was measured using the CyQUANT assay. The data were expressed as the average percentage of the untreated control (0 μg/mL
SHI) containing DMEM medium alone for 72 h and were pooled from the average data from five replicate experiments (with cells from 5 different patients)
in which each treatment was tested independently in triplicate. Error bars indicate mean +/− SEM (n= 5). *p< 0.05 versus the untreated control. Statistical
analysis was performed using One-way ANOVA and Tukey’s post-hoc test. b Representative images showing apoptosis induced by SHI treatment in Kc
and HSF respectively using TUNEL assay. Kc and HSF were treated with SHI for 72 h at the concentrations indicated, and then stained with TUNEL reagent
to detect apoptotic cells and DAPI to detect the nuclei of all cells. Cells were viewed and images were captured using a Nikon Eclipse TE2000-U system.
Green indicates DNA fragments from apoptotic cells, whereas blue localises the nuclei of both live and apoptotic cells. Representative images from cells
obtained from three patients are depicted. Scale bar: 0.2 mm. c Apoptotic rate (%) in Kc and HSF induced by SHI. Three randomly selected images were
recorded and the numbers of green-staining apoptotic cells and blue nuclei for all cells were counted. The final data was the average cell number
of nine different images from three different patients. Apoptotic rate = number of green cells / (number of green cells + number of blue
cells). Error bars indicate SEM
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tosis at 12 h compared to the untreated control (p < 0.05).
This data suggests that SHI at 3 μg/mL only induces
apoptosis in HSF but not in Kc after 12 h of treatment.
Effects of SHI on MAPK and intrinsic apoptosis signalling
pathways
Mechanisms underlying the proliferation-inhibiting and
apoptosis-inducing ability of SHI were determined using
western blot approaches (Fig. 3). Mitogen-activated pro-
tein kinases (MAPK), including ERK1/2, JNK1/2 and
p38α/β, have been widely demonstrated to play essential
roles in cell proliferation and apoptosis [18]. Those kinases
are activated by phosphorylation [19]. In addition, Bcl-2
can indirectly cleave caspase 3 by releasing cytochrome c
from the mitochondria [20]. Cleaved caspase 3 will then
further induce apoptosis [21]. As shown in Fig. 3a & b,Fig. 2 Apoptosis in Kc and HSF determined by flow cytometry. a Apoptosi
SHI-induced apoptosis in Kc and HSF. Kc and HSF were treated with 0, 1 or
iodide as per the manufacturer’s instructions. Flow cytometry was performe
were performed three times using cells from 3 patients. Triplicate treatmen
3 patients were pooled. *p < 0.05 versus the untreated controlincreases in phosphorylated ERK1/2 and JNK1/2 (p-ERK1/
2, p-JNK1/2), decreases in phosphorylated p38α/β (p-p38α/
β) and Bcl-2, as well as cleavage of caspase 3, were observed
in Kc at 48 h and in HSF at either 24 or 48 h after
exposure to 3 μg/mL SHI compared to the untreated
control (p < 0.05). These changes were also found in
HSF when treated with 1 μg/mL SHI for 48 h, but no
effect on Kc protein expression was detected at this
dose of SHI. Taken together these results indicate
that SHI increases p-ERK1/2 and p-JNK1/2, decreases
p38α/β and Bcl-2 and induces cleavage of caspase 3
in both Kc and HSF in a dose-dependent manner.
Again, these changes in protein expression occur
more rapidly (24 h) in HSF than Kc at the same dose
of SHI (3 μg/mL). SHI at 1 μg/mL can also trigger
these changes in HSF but does not induce changes in
these proteins in Kc.s rate in Kc and HSF following SHI treatment; b Quantitative analysis of
3 μg/mL SHI for 12 h and then stained with annexin V and propidium
d using FACSAria™ III Cell Sorter (Becton Dickinson). All experiments
ts were assessed in cells from each patient. Quantitative data from the
Fig. 3 Effects of SHI on cell protein expression. a Protein Expression in Kc; b Protein expression in HSF. Proteins were collected separately from
Kc and HSF treated with SHI for 24 and 48 h. The expression of proteins was detected using the Odyssey Infrared Imaging system. GAPDH was included as a loading control. For quantitative
analysis, the intensities of the bands were measured with densitometry and first normalized to GAPDH and then further converted to the percentage of the untreated control. The converted data
from 5 different patients were pooled together as shown in the figure. Representative images of the western blots are presented. Error bars indicate mean +/− SEM (n = 5). *p < 0.05 versus the











Fig. 4 Link between MAPK and intrinsic apoptosis signalling pathway. HSF were treated with SHI with or without U0126 (10 μM) or SP600125
(50 μM) for 24 h. Expression of protein was measured using the Odyssey Infrared Imaging system. All experiments were performed 3 times using
cells from 3 patients. Triplicate treatments were assessed in cells from each patient. The data was pooled as the percentage of the untreated
control. Representative images of the western blots are presented. Quantitative data were pooled from experiments using cells 3 different
patients. *p < 0.05
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pathway
As described above, we demonstrated that SHI
up-regulates p-ERK and p-JNK and down-regulates
p-p38, caspase 3 and Bcl-2 expression in Kc and HSF
in a dose-dependent manner. Reports in the literature
indicate that the MAPK proteins play roles in regulat-
ing cell apoptosis processes [22, 23]. To investigate
the roles of MAPK proteins in SHI-induced apoptosis,
the p-ERK inhibitor U0126 and the p-JNK inhibitor
SP600125 were used to block the phosphorylation of
ERK and JNK in HSF when treated with SHI. Theresults of this analysis (Fig. 4) indicated that U0126
significantly inhibits SHI-induced up-regulation of
p-ERK in HSF at 24 h. When HSF were treated with
both SHI (1 and 3 μg/mL) and U0126, there was no
reduction in Bcl-2 and cleaved caspase 3 was ob-
served, indicating that the blockage of p-ERK inter-
rupts SHI-induced down-regulation of Bcl-2 and
cleavage of caspase 3. However, reductions in Bcl-2
and cleavage of caspase 3 were detected when HSF
were treated with both SHI and SP600125, indicating
that blockage of p-JNK has no effect on SHI-induced
apoptosis in HSF.
Fig. 5 Effects of SHI on NF-κB signalling pathway. HSF were treated with SHI (0, 1 and 3 μg/mL) for 1, 24 or 48 h. Expression of protein was mea-
sured using the Odyssey Infrared Imaging system. All experiments were performed 3 times using cells from three patients. Triplicate treatments
were assessed in cells from each patient. The data was pooled as the percentage of the untreated control. Representative images of the western
blots are presented. Quantitative data were pooled from experiments using cells 3 different patients. *p < 0.05 versus the untreated control
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A large number of studies have reported that nuclear
factor-kappaB (NF-κB) plays essential roles in regulating
inflammation and apoptosis [24, 25]. NF-κB normally
binds with its inhibitor I-κB in an inactive state in the
cytoplasm [26]. Phosphorylation of I-κB kinase-α/β
(IKK-α/β) leads to the phosphorylation and subsequently
degradation of I-κB, thus inducing the phosphorylation
of NF-κB [27]. Activated (phosphorylated) NF-κB trans-
locates into the nucleus and then regulates the tran-
scription of its target genes, such as IL-1 and BCL2
[28]. As illustrated in Fig. 5, expression of total IKK-α/
β in HSF was attenuated when exposed to SHI at 3 μg/mL for 1 h compared to the control (p < 0.05). How-
ever, the expression of p-IKK-α/β remained at the same
level compared to the control. Down-regulation of p-I-
κB and up-regulation of p-NF-κB were observed in
HSF when exposed to SHI at 3 μg/mL for 24 and 48 h
compared to the control. This data indicates that SHI at
3 μg/mL activates the NF-κB signalling pathway in HSF.
Effects of SHI on cell gene expression
In addition to CASP3 and BCL2, other apoptosis-related
genes, namely BAX and CYCS [21] in both Kc and HSF,
and collagen production-related genes, including COL1A1,
COL3A1 and alpha-Smooth Muscle Actin (αSMA) [29] in
Fig. 6 Effects of SHI on cell gene expression. a Gene Expression in Kc; b Gene expression in HSF. Kc and HSF were treated with various
concentrations of SHI for 24 h and then total RNA was collected. After RNA extraction, first strand cDNA was synthesized. The cDNA sample was
then amplified using qRT-PCR. The expression of the target gene was first normalized to GAPDH and then further converted to the percentage of
the untreated control. Error bars indicate mean +/− SEM (n = 3). *p < 0.05 versus the untreated control. Statistical analysis was performed using
One-way ANOVA and Tukey’s post-hoc test
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in Fig. 6a, SHI at 3 μg/mL significantly attenuated
Kc CASP3 and BCL2 gene expression, while increas-
ing BAX and CYCS gene expression when compared
to the untreated control (p < 0.05). However, no ef-
fect at either 0.5 or 1 μg/mL SHI was observed on
Kc gene expression. SHI at 3 μg/mL significantly
down-regulated CASP3, BCL2, COL1A1, COL3A1
and αSMA and up-regulated BAX and CYCS expres-
sion in HSF compared to the untreated control (p <
0.05) (Fig. 6b). In addition, decreases in BCL2,Fig. 7 Effects of SHI on the expression of total TGF-β1 in Kc-HSF co-culture
then the “conditioned” media were collected. The concentration of TGF-β1
assay kit. The expression of TGF-β1 was then further converted to the perc
(n = 3). *p < 0.05 versus the untreated control. Statistical analysis was perforCOL1A1, COL3A1 and αSMA were observed in HSF
after exposure to SHI at 1 μg/mL compared to the
untreated control (p < 0.05). Furthermore, COL1A1
and αSMA gene expression were below the untreated
control (p < 0.05) in HSF exposed to 0.5 μg/mL SHI.
These data indicate that SHI regulates the expression
of the indicated apoptosis- and collagen production-
related genes in a dose-dependent manner. Interest-
ingly, SHI at 0.5 μg/mL inhibits COL1A1 and αSMA
gene expression without affecting apoptosis-related
gene expression. RT-PCR has also been performed to“conditioned” media. Cells were treated with SHI for 24 and 48 h and
was measured according to the standard curve provided with the
entage of the untreated control. Error bars indicate mean +/− SEM
med using One-way ANOVA and Tukey’s post-hoc test
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αSMA in Kc, however, the data obtained indicated
that these three genes are “Undetectable”.
SHI reduces TGF-β1 expression
TGF-β1, produced by both Kc and HSF [30], has been
broadly reported to play vital roles in wound healing
processes [31]. Of particular relevance, the over-
abundant expression of TGF-β1 in wound healing has
been reported to result in the formation of HS [32]. The
effect of SHI on total TGF-β1 expression in Kc-HSF co-
culture was therefore investigated using an ELISA assay
(Fig. 7). Our results suggest that total TGF-β1 expres-
sion is significantly reduced after exposed to SHI at 1
and 3 μg/mL for either 24 or 48 h compared to the un-
treated control (p < 0.05).
Discussion
Hypertrophic scarring remains a significant problem in
the clinic and the pathological mechanisms of HS are
poorly understood [6]. This is complicated by the fact
that the formation of HS may result from dysfunction in
any stage of the wound healing process [3].
Numerous reports have indicated that reduced apop-
tosis of fibroblasts at the end of wound healing results in
an increased number of active fibroblasts, and therebyFig. 8 Potential signalling pathways triggered when Kc and HSF are treate
or down-regulationinduces the formation of HS [2]. Indeed, it has been
reported that HS have a 4-fold decrease in cellular apop-
tosis compared with that found in normal wound scars
[33]. Consistent with our preliminary data, SHI has been
found in the studies reported herein to inhibit HSF pro-
liferation and induce HSF apoptosis in a dose-
dependent manner, even in the presence of co-cultured
Kc. Of relevance, ERK1/2, JNK1/2 and p38α/β have
been widely demonstrated to play vital roles in the regu-
lation of cell proliferation and apoptosis [18, 34, 35].
Thus, it has been demonstrated that MAPKs regulate
cell proliferation via mediating cell cycle progression
[36]. In quiescent cells, ERK1/2 are mostly located in
the cytoplasm, however, ERK1/2 accumulates in the nu-
cleus once extracellular stimulation occurs [37]. ERK1/2
then phosphorylates c-Fos protein and allows c-Fos to bind
with c-Jun to form an activator protein one (AP-1) complex
[38, 39]. AP-1, in turn, induces the expression of cyclin D1,
which stimulates the transition of the G1 to S phase of the
cell cycle by interacting with cyclin-dependent kinases [40].
Similarly, JNK1/2 have been found to play essential roles in
cell proliferation by supporting the formation of the AP-1
complex and transcription of cell cycle-related proteins
such as cyclin D1 [41]. In addition, p-38 has been shown to
regulate the cell cycle at the G1 to S and G2 to M transition
points [42].d with SHI. “ ” = activation or up-regulation; “ ” = inhibition
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regulation of apoptosis. For example, ERK1/2 regulates
cellular apoptosis by affecting the expression of caspases
[23]. Lee et al. demonstrated that p-ERK inhibitor signifi-
cantly prevents Perfluorohexane Sulfonate-induced apop-
tosis in PC12 pheochromocytoma cells [22]. JNK1/2 on
the other hand have been found to play an anti-apoptotic
role by blocking the release of cytochrome c in UV treated
fibroblasts [43]. In addition, studies by Qiu et al. reported
that phosphorylation of p38α/β induces apoptosis via in-
creasing oxidative stress and caspase-3 activity [44].
In light of this significant body of evidence, we exam-
ined which signal transduction pathways were involved
in mediating the effects of SHI. The data reported here
indicates that SHI-induced reduction of cell proliferation
in Kc and HSF may be triggered via the ERK1/2, JNK1/2
and p38α/β signalling pathways. In addition, our results
show that SHI induces apoptosis by differentially regu-
lating the expression of Bcl-2, Bax, Cytochrome c and
caspase 3. Moreover, our data demonstrated that p-ERK
is an up-stream regulator mediating the expression of
Bcl-2 and caspase 3. It has been reported that reduced
Bcl-2 and increased Bax expression leads to the release
of Cytochrome c from the mitochondria to the cyto-
plasm [45, 46]. Cytochrome c then combines with Apop-
totic protease activating factor 1(Apaf-1), which further
activates caspase 3 to trigger cell apoptosis [47]. These
putative mechanisms are schematically summarised in
Fig. 8.
NF-κB is another essential signalling pathway involved
in regulating cell apoptosis and inflammation [24, 25].
NF-κB is activated (phosphorylated) via the phosphoryl-
ation of IKK-α/β and degradation (phosphorylation) of I-
κB [27]. It has been reported that SHI induces apoptosis
in the cancer cell lines PANC-1, BxPC-3 and AsPC-1 by
suppressing the phosphorylation of NF-κB [48]. How-
ever, Kasibhatla et al. demonstrated that inhibition of
NF-κB activity leads to reduced apoptosis in hybridoma
cells [49]. Moreover, evidence indicates that activation of
NF-κB leads to increased transcription of anti-apoptotic
genes, such as Bcl-2, thus preventing cells from apop-
tosis [50]. Conversely, other studies suggest that activa-
tion of NF-κB is accompanied with decreased Bcl-2
expression [51]. Our studies, however, indicate degrad-
ation of I-κB and phosphorylation of NF-κB in HSF
when treated with SHI, suggesting a potential role for
NF-κB in SHI-induced apoptosis. Clearly, additional
studies are required to determine the exact roles of NF-
κB in this SHI-induced apoptosis in HSF; this could for
example be provided through the use of luciferase assays
to determine NF-κB-regulated gene transcription in HSF
when treated with SHI.
Kc also play important roles in wound healing and HS
formation. Indeed it has been reported that if woundclosure takes more than 21 days, then the probability of
the wound developing into a HS is more than 78 % [52].
Although our results show that SHI also inhibits Kc prolif-
eration and induces Kc apoptosis through the same signal-
ling pathways as in HSF, higher concentration of SHI
(3 μg/mL) are required to activate those signalling path-
ways in Kc compared to that observed in HSF. In other
words, SHI can inhibit HSF proliferation and induce HSF
apoptosis without affecting Kc function when applied at
specific concentrations (1 μg/mL). These results further
support the potential use of SHI as a novel scar treatment
since they suggest that SHI may be able to be applied to
inhibit excessive fibroblast proliferation during HS forma-
tion while having little effect on the re-epithelialization
function of Kc.
Another important factor underlying HS formation is
the over-abundant amount of collagen produced by fibro-
blasts [53]. In normal wound healing the high level of col-
lagen synthesis present in the early stages decreases and
returns to normal tissue levels as the wound closes [5].
Deficient degradation or excessive production of collagen
may therefore result in HS [7]. The data reported here in-
dicates that SHI significantly down-regulates COL1A1 and
COLA3A1 gene expression. In addition, αSMA, a marker
of myo-fibroblasts (a highly proliferative fibroblast type
that produces more collagen than normal fibroblasts) [29],
was also attenuated after SHI treatment. Interestingly,
0.5 μg/mL of SHI decreases COL1A1 and αSMA gene ex-
pression in HSF, while no effect of SHI on HSF prolifera-
tion or apoptosis was observed at this concentration.
These data suggest that it might be possible to deliver SHI
at concentrations that inhibit collagen production by fi-
broblasts without affecting cell proliferation.
Cytokines, such as TGF-β1 [54], Platelet-derived
Growth Factor (PDGF) [55] and Vascular Endothelial
Growth Factor (VEGF) [56], are also involved in wound
healing and HS formation processes. TGF-β1, a cytokine
secreted by both Kc and fibroblasts during wound healing,
has been reported to be up-regulated in HS tissues
[57, 58]. Furthermore, TGF-β1 from Kc stimulates fi-
broblasts to become myo-fibroblasts [59]. In contrast,
TGF-β1 secreted by fibroblasts induces Kc to return
to an inactive state at the end stage of wound healing
[60]. Our results suggest that SHI attenuates the ex-
pression of TGF-β1 in Kc-HSF co-culture conditioned
medium, further supporting the concept of SHI as a
potential therapy for HS. While we also employed
ELISA assays to examine the expression of PDGF and
VEGF, the concentration of PDGF and VEGF in the
Transwell® “conditioned” medium was too low to be
detected using ELISA. The effect of SHI on those cy-
tokines needs to be further evaluated using different
approaches, such as animal scar models, in future
studies.
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apoptotic or pro-apoptosis functions depending on the
type of cell [61], however, the exact mechanisms of
TGF-β1-induced apoptosis are still elusive. Jang et al.
demonstrated that TGF-β1 induces apoptosis in the hu-
man hepatoma cell line Hep3B via activating the death-
associated protein kinase (DAP-kinase) [62]. However,
Huang et al. reported that TGF-β1 prevents the human
lung carcinoma cell line A549 from serum deprivation-
induced apoptosis by reducing p-JNK expression [63].
Most relevant to wound healing, Karimizadeh et al. sug-
gested that TGF-β1 prevents dermal fibroblasts from
apoptosis [64]. To reveal the link between TGF-β1
reduction and SHI-induced apoptosis, further studies
using mono-cultured keratinocytes or fibroblasts are
required.
In conclusion, the excessive proliferation of fibroblasts,
over-abundant production of collagen and delayed Kc
function are three essential aspects linked to HS forma-
tion. SHI, an active component extracted from the Chin-
ese herb Radix Arnebiae, has been demonstrated here for
the first time to inhibit HSF proliferation and induce
apoptosis without affecting Kc function at select concen-
trations. In addition, SHI has been demonstrated to
reduce collagen production in HSF and attenuate TGF-β1
expression in Kc-HSF co-culture “conditioned” medium.Conclusions
The data generated from this study not only improves our
understanding of the bioactivities of SHI in a new range of
cells, but also suggests that SHI as a potential treatment
for HS warrants further investigation.
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